Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Katexco Pharmaceuticals
Toronto, Ontario, Canada
- Ownership
- Private
- Development stage
- Other
01
Overview
Katexco Pharmaceuticals aimed to develop the first oral therapies exploiting cannabinoid and nicotine receptor pathways in the brain to treat inflammatory diseases such as Crohn’s disease, gout, and multiple sclerosis. There is no evidence of clinical results or advancement to clinical trials as of the latest public records from 2018.
- Therapeutic areas
- GastroenterologyNeurologyImmunologyRheumatology
- Modalities
- Small moleculeNatural product-derived small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Katexco Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Katexco Pharmaceuticals.